• For Individuals
  • For Institutions
  • Download
  • Help
  • About

longbridgelongbridge
longbridgelongbridge
Why Longbridge?
Investment Products
Trading Tools
Trading Platform
Developers
Market Data Services
Analysis Tools
News Services
Dolphin Research
Pricing
Markets
Global Markets
Stock Screener
Information
Research
News
Live
Community
Academy
Promotions
PortAI
LB Café
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
Posts
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Nov24
Barclays Maintains Overweight Rating and Raises Target Price for Syndax Pharmaceuticals
18:57
Nov14
H.C. Wainwright and J.P. Morgan Reiterate Buy Rating on Syndax Pharmaceuticals
11:42
Nov4
Syndax Pharmaceuticals Reports Exceeding EPS Expectations for Q3, Stock Price Rises
17:23
Lawson Reiterates Buy Rating on Syndax Pharmaceuticals
07:56
Syndax Pharma released FY2025 Q3 earnings on November 3 After-Market EST, actual revenue USD 45.87 M (forecast USD 47.97 M), actual EPS USD -0.7009 (forecast USD -0.7389)
00:00
Syndax Pharma released FY2025 9 Months Earnings on November 3 After-Market EST, with actual revenue of USD 58 M and EPS of USD -1.8167
00:00

Schedules & Filings

Schedules
Filings
Nov3
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 45.87 M, Net Income -60.72 M, EPS -0.7009

Aug4
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 37.96 M, Net Income -71.85 M, EPS -0.8321

May5
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 20.04 M, Net Income -84.85 M, EPS -0.9846

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
SEVNR
0.0280
+218.18%
+0.019
SMX
141.000
+141.07%
+82.510
PLRZ
14.500
+104.51%
+7.410
PMI
3.690
+82.67%
+1.670
SNCR
8.710
+64.34%
+3.410
PMCB
1.210
+54.22%
+0.425
QCLS
6.920
+48.18%
+2.250
ANPA
21.860
+40.67%
+6.320
ASTX
46.070
+36.50%
+12.320
ABLV
0.9715
+34.87%
+0.251
View More